Introduction
Infinity Pharmaceuticals's main focus is to discover, develop and commercialize products for the treatment of diseases in the therapeutic area of oncology. The company seeks to build a franchise of oncology products through partnering with other pharmaceutical to gain access to funding, technical resources and intellectual property to further its development efforts.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Infinity Pharmaceuticals's product focus is on the discovery and development of drugs directed against specific molecular targets,which are referred as targeted therapies, hold the promise of being more selective than traditional cytotoxic drugs, thus harming fewer normal cells, reducing side effects and improving the quality of life for patients IPI-504 is Infinity's lead development program which is in the Phase I/II stage of drug development. The company currently has investigational compounds in clinical development for a wide range of diseases in the therapeutic area of oncology, including gastrointestinal stromal tumors, multiple myeloma and non-small-cell lung cancer. Infinity Pharmaceuticals derives its revenues from collaboration and licensing agreements. These revenues are related to various license fees, the reimbursement of research and development costs and contract service revenue received from its collaboration partners such as MedImmune and Novartis.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
Report Highlights
[Studien Infos ausblenden]
